T-CELLULAR CANCER IMMUNOTHERAPY AIMED AT A1 CYCLINE Russian patent published in 2017 - IPC C07K7/06 C07K7/08 A61K38/08 A61K38/10 A61P35/00 

FIELD: biotechnology.

SUBSTANCE: compositions and methods for induction of antigen-specific T-cell responses against human A1 (CCNA1) cyclin, which is defined herein as an antigen associated with leukemia, based on its overexpression in acute myeloid leukemia (AML), including leukemia stem cells (LSC) and in immunologically privileged cells of the testis, but not in other normal cell types. Immunotherapeutic approaches using such peptides for vaccines and preparation of therapeutic cells for adoptive transfer are also disclosed.

EFFECT: ability to induce an antigen-specific T-cell response to A1 human cyclin.

33 cl, 6 dwg, 1 ex